The Latest Breaking News from BMY

Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Increasing investments in R&D and rising expenditure on healthcare are expected to bolster the pharmaceutical sector's growth. Therefore, we think the stocks of fundamentally sound pharmaceutical companies Bristol-Myers Squibb (BMY), Bayer Aktiengesellschaft (BAYRY), and Catalyst Pharmaceuticals, Inc. (CPRX), which are currently trading at huge discounts to their peers, could be…

A whale with a lot of money to spend has taken a noticeably bullish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 14 strange trades.

Bristol Myers Squibb & Co's (NYSE:BMY) Phase 3 CheckMate -901 trial of Opdivo (nivolumab) plus Yervoy (ipilimumab) in urothelial carcinoma did not meet the primary endpoint of overall survival (OS) at the final analysis. The trial compared Opdivo + Yervoy to standard-of-care chemotherapy as a first-line treatment for unresectable or metastatic urothelial carcinoma…

BridgeBio Pharma Inc (NASDAQ:BBIO) has announced an exclusive license with Bristol Myers Squibb Co (NYSE:BMY) to develop and commercialize BBP-398, a potentially best-in-class SHP2 inhibitor, in oncology.  Under the agreement terms, BridgeBio will receive an upfront payment of $90 million, up to $815 million in development, regulatory and sales milestone payments, and tiered royalties in…

Someone with a lot of money to spend has taken a bullish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

The Fed’s aggressive interest rate hikes and high energy prices will likely fuel recessionary conditions. Moreover, the unexpected decline in GDP in the first quarter indicates a possible economic contraction. Amid such possibilities, the pharmaceutical industry could attract investors’ attention because of the inelastic demand for its products. Today, I…

The stock market has been faced with significant volatility on concerns over surging inflation, the Fed’s anticipated interest rate hikes, and continuing geopolitical instability. However, the market selloffs have created an attractive opportunity to buy quality large-cap stocks at low prices. We believe fundamentally sound large-cap stocks Bristol (BMY), Micron…

Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Bristol Myers Squibb cut its 2022 guidance Friday amid patent losses and Revlimid erosion. In response, BMY stock tumbled.

Bristol-Myers Squibb Co (NYSE:BMY) has posted Q1 revenues of $11.65 billion, an increase of 5% Y/Y (7% constant currency), beating the consensus of $11.36 billion.  Eliquis, Opdivo, cell therapy products, and Reblozyl drove sales growth. Eliquis sales increased 11% to $3.21 billion, Opdivo sales increased 12% to $1.92 billion, and Yervoy sales…